These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35189322)

  • 1. Chemokine clouding and liver cancer heterogeneity: Does it impact clinical outcomes?
    Ahmad M; Dhasmana A; Harne PS; Zamir A; Hafeez BB
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):1175-1185. PubMed ID: 35189322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory microenvironment and expression of chemokines in hepatocellular carcinoma.
    Han KQ; He XQ; Ma MY; Guo XD; Zhang XM; Chen J; Han H; Zhang WW; Zhu QG; Nian H; Ma LJ
    World J Gastroenterol; 2015 Apr; 21(16):4864-74. PubMed ID: 25944999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling molecules in the microenvironment of hepatocellular carcinoma.
    Chen W; Tan M; Zhang H; Gao T; Ren J; Cheng S; Chen J
    Funct Integr Genomics; 2024 Aug; 24(5):146. PubMed ID: 39207523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-associated fibroblasts promote hepatocellular carcinoma metastasis through chemokine-activated hedgehog and TGF-β pathways.
    Liu J; Chen S; Wang W; Ning BF; Chen F; Shen W; Ding J; Chen W; Xie WF; Zhang X
    Cancer Lett; 2016 Aug; 379(1):49-59. PubMed ID: 27216982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity of hepatocellular carcinoma contributes to cancer progression.
    Jeng KS; Chang CF; Jeng WJ; Sheen IS; Jeng CJ
    Crit Rev Oncol Hematol; 2015 Jun; 94(3):337-47. PubMed ID: 25680939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New perspectives on chemokines in hepatocellular carcinoma therapy: a critical pathway for natural products regulation of the tumor microenvironment.
    Ruishi X; Linyi X; Yunfan B; Wenbo Y; Xiaoying Z; Xiaoxue F; Difu Z; Xintian L; Ming Z; Haoming L
    Front Immunol; 2024; 15():1456405. PubMed ID: 39206194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-induced myeloid derived growth factor promotes hepatocellular carcinoma progression through remodeling tumor microenvironment.
    Wang X; Mao J; Zhou T; Chen X; Tu H; Ma J; Li Y; Ding Y; Yang Y; Wu H; Tang X
    Theranostics; 2021; 11(1):209-221. PubMed ID: 33391471
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of chemokines in hepatocellular carcinoma (Review).
    Xue D; Zheng Y; Wen J; Han J; Tuo H; Liu Y; Peng Y
    Oncol Rep; 2021 Mar; 45(3):809-823. PubMed ID: 33650640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemokine CXCL1 may serve as a potential molecular target for hepatocellular carcinoma.
    Han KQ; Han H; He XQ; Wang L; Guo XD; Zhang XM; Chen J; Zhu QG; Nian H; Zhai XF; Jiang MW
    Cancer Med; 2016 Oct; 5(10):2861-2871. PubMed ID: 27682863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aging-related features predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.
    Hong T; Su W; Pan Y; Tian C; Lei G
    Front Immunol; 2022; 13():951459. PubMed ID: 36189258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCL2/10/12/14 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma.
    Lin T; Zhang E; Mai PP; Zhang YZ; Chen X; Peng LS
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34085699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma.
    Hong YK; Li Y; Pandit H; Li S; Pulliam Z; Zheng Q; Yu Y; Martin RCG
    Cell Immunol; 2019 Feb; 336():66-74. PubMed ID: 30626493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid hormone in the regulation of hepatocellular carcinoma and its microenvironment.
    Manka P; Coombes JD; Boosman R; Gauthier K; Papa S; Syn WK
    Cancer Lett; 2018 Apr; 419():175-186. PubMed ID: 29414304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased mRNA expression of chemokines in hepatocellular carcinoma with tumor-infiltrating lymphocytes.
    Hirano S; Iwashita Y; Sasaki A; Kai S; Ohta M; Kitano S
    J Gastroenterol Hepatol; 2007 May; 22(5):690-6. PubMed ID: 17444857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular heterogeneity and plasticity in liver cancer.
    Chan LK; Tsui YM; Ho DW; Ng IO
    Semin Cancer Biol; 2022 Jul; 82():134-149. PubMed ID: 33647386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma.
    Tang Y; Guo C; Yang Z; Wang Y; Zhang Y; Wang D
    Front Immunol; 2022; 13():862527. PubMed ID: 35493471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemokine expression in hepatocellular carcinoma versus colorectal liver metastases.
    Rubie C; Frick VO; Wagner M; Weber C; Kruse B; Kempf K; König J; Rau B; Schilling M
    World J Gastroenterol; 2006 Nov; 12(41):6627-33. PubMed ID: 17075975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.
    Dai X; Guo Y; Hu Y; Bao X; Zhu X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Fang W
    Theranostics; 2021; 11(7):3489-3501. PubMed ID: 33537099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications.
    Safri F; Nguyen R; Zerehpooshnesfchi S; George J; Qiao L
    Cancer Gene Ther; 2024 Aug; 31(8):1105-1112. PubMed ID: 38499648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma.
    Wang J; Ling S; Ni J; Wan Y
    BMC Cancer; 2022 Jun; 22(1):638. PubMed ID: 35681134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.